Recombinant human parathyroid hormone (PTH) causes bone density to increase by its ability to maintain calcium and phosphorus levels as new bone is formed.In which population is this agent not approved for treatment?
A) Postmenopausal women with severe bone loss
B) Men with osteoporosis who have a high risk of fractures
C) Persons who have not improved on bisphosphonate therapy
D) Perimenopausal women with a family history of osteoporosis
Correct Answer:
Verified
Q19: When a patient has a calcium deficiency,a
Q20: What is the mechanism of action of
Q21: Which is a potential dietary interaction with
Q22: What is one indication for the use
Q23: What is the current recommendation of the
Q25: For which patient population must a clinician
Q26: What important patient education point should be
Q27: What unique property does calcitonin possess compared
Q28: Women between the ages of 15 and
Q29: Where is calcitonin produced in humans?
A)Thyroid gland
B)Pancreas
C)Pituitary
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents